A decade ago, diagnosing Alzheimer's disease meant costly PET scans or invasive spinal taps. Today, a single vial of blood can do the job. That shift captures the essence of the Blood-Based Biomarkers Market, which is valued at USD 8.50 billion in 2025 and is projected to nearly double to USD 18.50 billion by 2034, growing at a robust 9.0% CAGR. This growth isn't accidental — it's being driven by the collision of an aging global population, a rising cancer burden, and one of the most consequential diagnostic breakthroughs of the decade: the arrival of validated blood tests for Alzheimer's disease.
Why the Blood-based biomarkers Market Is Surging
Blood-based biomarkers — proteins, nucleic acids, cells, and metabolites detectable in blood — are replacing invasive biopsies and imaging across oncology, cardiology, neurology, and metabolic disease. The International Agency for Research on Cancer projects cancer cases will climb from 20 million in 2022 to 35 million by 2050, fueling demand for liquid biopsy and circulating tumor DNA testing. Genetic biomarkers already dominate the market with a 41% share, while oncology leads applications at 39%, reflecting how central non-invasive cancer monitoring has become to modern medicine.
But the real inflection point is neurology. The 2025 FDA clearance of the first blood test to aid Alzheimer's diagnosis — Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test — opened an entirely new category: the Blood-Based Biomarker for Alzheimer's Disease Diagnostics Market. Within months, Labcorp launched the test nationwide, and Roche followed with FDA clearance for its Elecsys pTau181 primary-care assay. The Alzheimer's Association's first clinical practice guideline, endorsing these tests for triage and even substitution for imaging in appropriate patients, has effectively fast-tracked adoption across health systems.
Fujirebio's Bet on the Brain
So what is Fujirebio's vision for the future of blood-based biomarkers for neurological disorders compared to its competitors? Fujirebio is positioning itself as the pioneer that proved plasma biomarkers could match the diagnostic confidence of PET imaging and cerebrospinal fluid testing — without the cost or discomfort. Its strategy centers on phosphorylated tau markers (pTau217), and its December 2024 memorandum of understanding with Eisai for joint research into neurodegenerative biomarkers signals an ambition to move beyond single-test clearances toward a broader ecosystem of companion diagnostics tied to disease-modifying therapies.
How is Fujirebio positioned within the neurodegenerative disease diagnostics space, and how does this compare with key competitors in terms of biomarkers, technologies, and partnerships? Fujirebio holds a first-mover advantage as the only company with an FDA-cleared blood-based amyloid pathology test, giving it a head start in clinical trust and reimbursement pathways. Roche runs a close second, leveraging its Elecsys platform and earlier Breakthrough Device Designation (alongside Eli Lilly) for pTau217 to push into primary-care settings — a segment Fujirebio has yet to fully penetrate. Meanwhile, Quanterix brings ultra-sensitive single-molecule array technology capable of detecting even lower-abundance neurological proteins, and its partnerships, like Biogen's collaboration with Beckman Coulter and Fujirebio itself, show how the competitive landscape is increasingly defined by alliances rather than solo development. Fujirebio's edge lies in regulatory precedent; Roche's lies in primary-care reach; Quanterix competes on raw analytical sensitivity.
Where Thermo Fisher Fits In
To evaluate Thermo Fisher Scientific on the use of biomarkers in neurodegenerative diseases, the company's strength lies less in single-assay clearances and more in platform breadth. Thermo Fisher's mass spectrometry and proteomics infrastructure supports biomarker discovery and multiplexed panel development, positioning it as an enabler for other diagnostics developers rather than a direct challenger for Alzheimer's test clearances. Its role is foundational — powering the research and validation studies that eventually produce clinically approved neurological tests — making it a quiet but essential player in the neurodegenerative diagnostics pipeline.
The Road Ahead
North America currently commands 44% of global revenue, driven by regulatory leadership and dense diagnostics infrastructure, while Asia-Pacific is the fastest-growing region as healthcare access expands across China, Japan, and India. As artificial intelligence, multi-biomarker panels, and ultra-sensitive detection technologies mature, the market is shifting from single-marker diagnostics toward predictive, risk-based precision medicine — cementing blood-based testing as foundational infrastructure for the next generation of preventive healthcare.
Latest Reports Offered by Delveinsight
compartment syndrome market | bladder scanners market | sandhoff disease market | pro-opiomelanocortin pomc deficiency obesity market | acute radiation syndrome market | lip and oral cavity cancer market | ocular motility disturbance market | osteochondromas market | pneumothorax treatment devices market | pulmonology devices market | restless legs syndrome market | zika virus market | resorbable vascular scaffold market | advanced cancer pain management market | chronic wounds market | shingles market | erectile dysfunction market | congenital diarrheal disorders market | antibody drug conjugate market | hypoventilation market
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk